UK clinical genomics company Congenica secured a further 13.25 million pounds ($17.3 million) in Series B round.
Parkwalk Advisors led the round with participation from Digital China Health Technologies Corp. Ltd. as well as existing investors. The new round brings total funding raised by Congenica to date to $33.5 million.
Congenica plans to use the money raised from the funding to accelerate growth, with commercial scale-up to support further penetration into international markets, and expand on the initial focus of the U.S. and China.
Furthermore, the company will also use the new funds to develop an enhanced product platform that harnesses the power of statistics and machine learning technology to augment the ability of users to make diagnostic decisions.